Efficacy of Tolterodine versus Oxybutynin in treatment of enuresis

Clinical trial of comparison of the efficacy of Tolterodine versus Oxybutynin in treatment of enuretic children resistant to Desmopressin

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141224020419N3

Enrollment

Registered

2019-07-02

Start date

2018-11-22

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Noctural enuresis. Unspecified urinary incontinence

Interventions

Intervention 1: Intervention first group: The group receiving tolterodine (Made by Iran Daroo Co, 05-4 mg every night) 0.5 mg every night after dinner than could be titrated to 4 mg + desmopressin (Ma

Eligibility

Sex/Gender

All

Age

5 Years to 18 Years

Inclusion criteria

Inclusion criteria: Primary enuresis No evidence of secondary enuresis in clinical examination, urine analysis and sonography No response to nasal desmopressine

Exclusion criteria

Exclusion criteria: Secondary enuresis Underlying genitourinary system anomalies Interruption of follow up of the patient

Design outcomes

Primary

Measure	Time frame
Noctural enuresis in night. Timepoint: Beginning of the study, 6 and 12 weeks after beginning of the study. Method of measurement: The frequency of wetting every night.;Noctural enuresis in week. Timepoint: Beginning of the study, 6 and 12 weeks after beginning of the study. Method of measurement: The frequency of wetting in week.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamid Mohammadjaafari

Sari University of Medical Sciences

hamidmjaafari@yahoo.com+98 11 3334 2334

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026